Orchid Island Capital Inc
Change company Symbol lookup
Select an option...
ORC Orchid Island Capital Inc
ORAN Orange SA
OKE ONEOK Inc
OHI Omega Healthcare Investors Inc
OGE OGE Energy Corp
ODFL Old Dominion Freight Line Inc
O Realty Income Corp
NYMT New York Mortgage Trust Inc
NVO Novo Nordisk A/S
NUGT Direxion Daily Gold Miners Index Bull 2X Shares
Go

Financials : Mortgage Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Orchid Island Capital, Inc. is a specialty finance company that invests in residential mortgage-backed securities (RMBS). The Company's business objective is to provide attractive risk-adjusted total returns to its investors over the long term through a combination of capital appreciation and the payment of regular monthly distributions. Its portfolio consists of two categories of Agency RMBS: pass-through Agency RMBS and structured Agency RMBS. It invests in pass-through securities, which are securities secured by residential real property in which payments of both interest and principal on the securities are generally made monthly. The mortgage loans underlying pass-through certificates are classified into three categories, including fixed-rate mortgages, adjustable-rate mortgages (ARMs) and Hybrid ARMs. It invests in structured Agency RMBS, which include collateralized mortgage obligations, interest only securities, inverse interest only securities and principal only securities.

Closing Price
$5.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
885,428
0

ElectroCore's stock rockets in active trading after EUA issued for its gammaCore Saphire CV

1:48 pm ET July 13, 2020 (MarketWatch)
Print

Shares of electroCore Inc. (ECOR) more than doubled (up 155%) on very heavy volume in afternoon trading Monday, after the bioelectronic medicine company said it was issued an emergency use authorization (EUA) by the Food and Drug Administration OK'ing the use of its gammaCore Sapphire CV to help in the treatment of COVID-19 patients. Trading volume soared to 136.7 million shares, enough to make the stock the most actively traded on the Nasdaq exchange, and compared with the full-day average of about 1.1 million shares. "Needless to say, we are very pleased to have received this EUA, and we intend work vigorously to make this novel therapy available to physicians treating known or suspected COVID 19 patients who are experiencing exacerbation of asthma-related breathing difficulty," said Chief Executive Dan Goldberger. The stock has rallied 36% year to date, while the S&P 500 is little changed.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 13, 2020 13:48 ET (17:48 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.